Updated:
Noro-Moseley Partners
Noro-Moseley Partners provides early growth equity for rapidly-scaling B2B technology and healthcare companies. The firm has been partnering with exceptional...
Noro-Moseley Partners
Noro-Moseley Partners provides early growth equity for rapidly-scaling B2B technology and healthcare companies. The firm has been partnering with exceptional teams since 1983 and works with strong CEOs of high-growth businesses to scale. It actively invests in businesses with 50%+ year-over-year growth, compelling unit economics, target revenue run rates of $2M–20M, and target investments of $5–20M.
General information
Firm type
Private Equity
Year founded
1983
Location
Region
North America
Country
United States
City
Atlanta
Corporate office
Atlanta, GA, United States
Sector focus
Frequently asked questions
How does Noro-Moseley Partners source its healthcare deals?
NMP cultivates distribution relationships with a curated group of health-plan and health-system investors that collectively cover 45 million lives, giving portfolio companies direct access to enterprise healthcare purchasers. The firm also draws on its 40-year network and the domain expertise of its operating advisor group to identify businesses with proven unit economics before they pursue institutional capital.
How involved does Noro-Moseley get with portfolio company operations?
NMP takes an active board role focused on CEO support, executive team recruitment, sales and marketing instrumentation, and exit-process management. The firm provides operating advisors who are former entrepreneurs and executives, and it has guided multiple companies through transitions from services to SaaS models before exit.
Does Noro-Moseley Partners invest outside the United States?
NMP invests exclusively in US-headquartered companies, with active portfolio operations in Texas, New York, Ohio, Michigan, Minnesota, Florida, Georgia, Idaho, and North Carolina. The firm describes its geographic focus as emerging technology and healthcare hubs across the United States.
What is the firm's realized exit track record?
The current NMP team has generated exits representing over $5 billion in aggregate enterprise value since 2015 (per firm website). Notable realized exits include Red Canary (acquired by Zscaler), Contessa (acquired by Amedisys), SupplyPike (acquired by SPS Commerce), Clearleap (acquired by IBM), and Trendkite (acquired by Cision).
Who leads investment decisions at Noro-Moseley Partners?
NMP's public team page describes the group as having over 70 years of collective investment experience, but the firm does not name individual managing partners, general partners, or an investment committee on its website. Investment decisions appear to be made collaboratively by the core investment team based in Atlanta.
What sectors does Noro-Moseley explicitly avoid?
NMP restricts its mandate to B2B technology and healthcare companies, including enterprise software, AI-enabled platforms, healthcare IT, and tech-enabled services. The firm has no disclosed interest in consumer-facing businesses, hardware, deep tech outside of AI/ML, or capital-intensive sectors like manufacturing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: